Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CLEC4M | Q9H2X3 | 3/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25506227 | 0.93 | LGALS3 (0.51) | LGALS3GLAPKMCLEC4M | |
| SCHEMBL25979960 | 0.91 | LGALS3 (0.37) | LGALS3GLAGBA1PKMCLEC4M | |
| SCHEMBL25506055 | 0.88 | LGALS3 (0.41) | LGALS3GLAGBA1CLEC4M | |
| SCHEMBL25505788 | 0.87 | LGALS3 (0.40) | LGALS3GLAGBA1CLEC4MOPRM1 | |
| SCHEMBL25505637 | 0.87 | LGALS3 (0.44) | LGALS3PKMCLEC4MOPRM1 | |
| SCHEMBL25523201 | 0.87 | LGALS3 (0.44) | LGALS3PKMCLEC4MOPRM1 | |
| SCHEMBL25908468 | 0.87 | LGALS3 (0.56) | LGALS3GLACLEC4M | |
| SCHEMBL25979532 | 0.84 | LGALS3 (0.40) | LGALS3GLAGBA1CLEC4M | |
| SCHEMBL25344774 | 0.82 | LGALS3 (0.49) | LGALS3GLAPKMCLEC4MOPRM1 | |
| SCHEMBL25346846 | 0.82 | LGALS3 (0.47) | LGALS3GLAGBA1CLEC4M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | LGALS3 264/4885GLA 384/4885GBA1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.